uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Mutation in NRAS in familial Noonan syndrome: case report and review of the literature
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medicinsk genetik och genomik.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Medicinsk genetik och genomik.
Gothenburg Univ, Sahlgrenska Acad, Dept Paediat, Gothenburg, Sweden..
Katholieke Univ Leuven, Dept Human Genet, Leuven, Belgium..
Show others and affiliations
2015 (English)In: BMC Medical Genetics, ISSN 1471-2350, E-ISSN 1471-2350, Vol. 16, 95Article in journal (Refereed) Published
Abstract [en]

Background: Noonan syndrome (NS), a heterogeneous developmental disorder associated with variable clinical expression including short stature, congenital heart defect, unusual pectus deformity and typical facial features, is caused by activating mutations in genes involved in the RAS-MAPK signaling pathway. Case presentation: Here, we present a clinical and molecular characterization of a small family with Noonan syndrome. Comprehensive mutation analysis of NF1, PTPN11, SOS1, CBL, BRAF, RAF1, SHOC2, MAP2K2, MAP2K1, SPRED1, NRAS, HRAS and KRAS was performed using targeted next-generation sequencing. The result revealed a recurrent mutation in NRAS, c.179G > A (p.G60E), in the index patient. This mutation was inherited from the index patient's father, who also showed signs of NS. Conclusions: We describe clinical features in this family and review the literature for genotype-phenotype correlations for NS patients with mutations in NRAS. Neither of affected individuals in this family presented with juvenile myelomonocytic leukemia (JMML), which together with previously published results suggest that the risk for NS individuals with a germline NRAS mutation developing JMML is not different from the proportion seen in other NS cases. Interestingly, 50 % of NS individuals with an NRAS mutation (including our family) present with lentigines and/or Cafe-au-lait spots. This demonstrates a predisposition to hyperpigmented lesions in NRAS-positive NS individuals. In addition, the affected father in our family presented with a hearing deficit since birth, which together with lentigines are two characteristics of NS with multiple lentigines (previously LEOPARD syndrome), supporting the difficulties in diagnosing individuals with RASopathies correctly. The clinical and genetic heterogeneity observed in RASopathies is a challenge for genetic testing. However, next-generation sequencing technology, which allows screening of a large number of genes simultaneously, will facilitate an early and accurate diagnosis of patients with RASopathies.

Place, publisher, year, edition, pages
2015. Vol. 16, 95
Keyword [en]
NRAS, Noonan syndrome, Mutation, RAS-MAPK pathway, RASopathies
National Category
Medical Genetics
URN: urn:nbn:se:uu:diva-265813DOI: 10.1186/s12881-015-0239-1ISI: 000362706100001PubMedID: 26467218OAI: oai:DiVA.org:uu-265813DiVA: diva2:866658
Swedish Research Council
Available from: 2015-11-03 Created: 2015-11-03 Last updated: 2015-11-03Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedFulltext

Search in DiVA

By author/editor
Wilbe, MariaAnnerén, GöranBondeson, Marie-Louise
By organisation
Medicinsk genetik och genomik
In the same journal
BMC Medical Genetics
Medical Genetics

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 225 hits
ReferencesLink to record
Permanent link

Direct link